Caribou Biosciences (CRBU) Competitors

Rapport Therapeutics (NASDAQ:RAPP) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation.

Is RAPP or CRBU more profitable?

Rapport Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,290.81%. Rapport Therapeutics' return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	N/A	N/A
Caribou Biosciences	-1,290.81%	-45.46%	-38.07%

Does the MarketBeat Community believe in RAPP or CRBU?

Caribou Biosciences received 24 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Rapport Therapeutics an outperform vote while only 62.79% of users gave Caribou Biosciences an outperform vote.

Company	Underperform	Outperform
Rapport Therapeutics	Outperform Votes 3 75.00%	Underperform Votes 1 25.00%
Caribou Biosciences	Outperform Votes 27 62.79%	Underperform Votes 16 37.21%

Which has preferable valuation and earnings, RAPP or CRBU?

Rapport Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$34.79M	-$3.45	-3.81
Caribou Biosciences	$9.92M	11.44	-$102.07M	-$1.62	-0.75

Do institutionals and insiders hold more shares of RAPP or CRBU?

77.5% of Caribou Biosciences shares are owned by institutional investors. 8.3% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Does the media favor RAPP or CRBU?

In the previous week, Caribou Biosciences had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 5 mentions for Caribou Biosciences and 4 mentions for Rapport Therapeutics. Caribou Biosciences' average media sentiment score of 1.29 beat Rapport Therapeutics' score of 0.22 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rapport Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate RAPP or CRBU?

Rapport Therapeutics presently has a consensus price target of $32.67, suggesting a potential upside of 148.23%. Caribou Biosciences has a consensus price target of $8.50, suggesting a potential upside of 596.72%. Given Caribou Biosciences' higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Caribou Biosciences	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Caribou Biosciences beats Rapport Therapeutics on 9 of the 14 factors compared between the two stocks.